Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | Director · 10% owner | December 16, 2025 | December 18, 2025 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 13, 2018 | June 15, 2018 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director | June 22, 2018 | June 22, 2018 |
| GERON CORPGERN · Entity 4989 | Director | May 15, 2018 | May 17, 2018 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
| Peak Bio, Inc.PKBO · Entity 85431 | Director · 10% owner | November 14, 2024 | November 18, 2024 |
| Rezolute, Inc.ANTB · Entity 1990 | Director · Chairman, Scientific Adv. Bd. | October 31, 2016 | January 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to purchase American Depositary Shares ("ADRs")SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 | Direct | 618,658 |
Reported balance
After 2025-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-16 · Purchase · Acquired 618,658 · Balance 618,658 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. |
| Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 618,658 |
Reported balance
After 2025-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-16 · Purchase · Acquired 618,658 · Balance 618,658 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7: Conversion Exercise Price of Security is $0.00001 F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. |
| Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,093,293 |
Reported balance
After 2025-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-16 · Purchase · Acquired 3,093,293 · Balance 3,093,293 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F7: Conversion Exercise Price of Security is $0.00001 F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. |
| Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.39 | Direct | 3,093,293 |
Reported balance
After 2025-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-16 · Purchase · Acquired 3,093,293 · Balance 3,093,293 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants").
F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
F7: Conversion Exercise Price of Security is $0.00001
CytomX Therapeutics, Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2028-06-12 | Direct | 14,000 |
Reported balance
After 2018-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 14,000 · Balance 14,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Eidos Therapeutics, Inc.
Report date June 22, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2028-06-21 | Direct | 83,750 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Grant · Acquired 83,720 · Balance 83,750 F1: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the "Grant") on June 22, 2018 (the "Grant Date"). The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the "Grant") on June 22, 2018 (the "Grant Date"). The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date
GERON CORP
Report date May 15, 2018 · Filed May 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2028-05-14 | Direct | 70,000 |
Reported balance
After 2018-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-15 · Grant · Acquired 70,000 · Balance 70,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Peak Bio, Inc.
Report date November 14, 2024 · Filed November 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,574,661 |
Reported balance
After 2024-11-14 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-11-14 · Conversion · Acquired 4,574,661 · Balance 4,574,661 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-11-14 · Disposition to issuer · Disposed 4,574,661 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-11-14 · Disposition to issuer · Disposed 8,382,742 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-11-14 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-11-14 · Disposition to issuer · Disposed 372,940 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F4: The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC. |
| Convertible NotesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-14 · Conversion · Disposed Not disclosed · Balance 0 F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). |
| Warrant (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-14 · Disposition to issuer · Disposed 176,292 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-14 · Disposition to issuer · Disposed 1,200,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F6: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock").
F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent.
F4: The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC.
F5: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio.
F6: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio.
Rezolute, Inc.
Report date October 31, 2016 · Filed January 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2026-10-31 | Direct | 4,000,000 |
Reported balance
After 2016-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-31 · Grant · Acquired 4,000,000 · Balance 4,000,000 F1: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. F2: The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria.
F2: The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 17:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000100 · wk-form4_1781298056.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:57 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 3,093,293 | $0.40 Strike: $0.00 | $1,249,999.70 |
DisclosureSEC source: 0001493152-25-028420 · ownership.xml · derivative · entry 4 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,093,293 Underlying: American Depositary Shares representing Ordinary Shares · 3,093,293 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:57 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase ADRs · Derivative | 3,093,293 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028420 · ownership.xml · derivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,093,293 Underlying: American Depositary Shares representing Ordinary Shares · 3,093,293 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:57 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 618,658 | $0.40 Strike: $0.00 | $249,999.70 |
DisclosureSEC source: 0001493152-25-028420 · ownership.xml · derivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,658 Underlying: American Depositary Shares representing Ordinary Shares · 618,658 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:57 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative | 618,658 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028420 · ownership.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,658 Underlying: American Depositary Shares representing Ordinary Shares · 618,658 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:43 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001746473-25-000125 · wk-form4_1749516175.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043936 · ownership.xml · derivative · entry 4 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: American Depositary Shares representing Ordinary Shares · 225,000 shares Expires 2035-03-20 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043936 · ownership.xml · derivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: American Depositary Shares representing Ordinary Shares · 175,000 shares Expires 2035-03-20 F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 17:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries B Warrants (Right to Buy) · Derivative | 892,857 | $1.12 Strike: $0.87 | $999,999.84 |
DisclosureSEC source: 0000950170-25-036488 · ownership.xml · derivative · entry 4 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892,857 Underlying: American Depositary Shares representing Ordinary Shares · 892,857 shares Expires 2030-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 17:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries A Warrants (Right to Buy) · Derivative | 892,857 | $1.12 Strike: $0.87 | $999,999.84 |
DisclosureSEC source: 0000950170-25-036488 · ownership.xml · derivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892,857 Underlying: American Depositary Shares representing Ordinary Shares · 892,857 shares Expires 2026-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 17:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 892,857 | $1.12 | $999,999.84 |
DisclosureSEC source: 0000950170-25-036488 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,695,854 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,200,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · derivative · entry 7 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F6 · kind: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. F6 · derivative.exercise_date: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. F6 · derivative.expiration_date: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | Disposition to issuerWarrant (Right to Purchase) · Derivative | 176,292 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · derivative · entry 6 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 176,292 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F5 · kind: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio. F5 · price: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio. F5 · derivative.exercise_date: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio. F5 · derivative.expiration_date: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | ConversionConvertible Notes · Derivative | Not disclosed | Not disclosed | $2,130,775.00 |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · derivative · entry 5 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,574,661 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2 · kind: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · price: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · derivative.expiration_date: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | Disposition to issuerCommon Stock | 372,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · nonDerivative · entry 4 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F4 · ownership.nature: The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | Disposition to issuerCommon Stock | 8,382,742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · nonDerivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | Disposition to issuerCommon Stock | 4,574,661 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · kind: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F3 · price: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 18:53 UTC | Peak Bio, Inc. PKBO · Entity 85431 | ConversionCommon Stock | 4,574,661 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128149 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,574,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2 · kind: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F2 · price: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:16 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 26,764 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001746473-24-000106 · wk-form4_1718669767.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,764 Underlying: Common Stock · 26,764 shares Expires 2034-06-13 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-049688 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,382,742 F1 · price: On September 21, 2023, Dr. Hoyoung Huh purchased a total of 45,000 shares of the Company's Common Stock at prices ranging from $0.19 per share to $0.21 per share. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-049173 · ownership.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,337,742 F2 · price: On September 20, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.19 per share to $0.21 per share. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-049173 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,307,742 F1 · price: On September 19, 2023, Dr. Hoyoung Huh purchased a total of 50,000 shares of the Company's Common Stock at prices ranging from $0.207 per share to $0.22 per share. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-048771 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,257,742 F1 · price: On September 15, 2023, Dr. Hoyoung Huh purchased a total of 25,000 shares of the Company's Common Stock at prices ranging from $0.265 per share to $0.275 per share. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-048367 · ownership.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,232,742 F2 · price: On September 14, 2023, Dr. Hoyoung Huh purchased a total of 20,000 shares of the Company's Common Stock at prices ranging from $0.26 per share to $0.275 per share. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-048367 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,212,742 F1 · price: On September 13, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.271 per share to $0.28 per share. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 17,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-047919 · ownership.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,182,742 F2 · price: On September 12, 2023, Dr. Hoyoung Huh purchased a total of 17,000 shares of the Company's Common Stock at prices ranging from $0.275 per share to $0.28 per share. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-047919 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,165,742 F1 · price: On September 11, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.28 per share to $0.32 per share. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 13,000 | $0.27 | $3,445.00 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 7 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,228,992 Read SEC document |
| August 31, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 7 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 56,100 | $0.26 | $14,305.50 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 6 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,215,992 Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 11,400 | $0.27 | $3,021.00 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 5 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,159,892 Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 3,750 | $0.25 | $941.25 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 4 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,148,492 Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 2,500 | $0.26 | $650.00 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,144,742 Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 1,000 | $0.25 | $253.00 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,142,242 Read SEC document |
| August 30, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 6 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 30, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 5 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 30, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 4 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 30, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 30, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 29, 2023 Filed Sep 1, 2023 16:05 UTC | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 5,500 | $0.25 | $1,375.00 |
DisclosureSEC source: 0000950170-23-046053 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,141,242 Read SEC document |
| August 29, 2023 Filed Sep 12, 2023 16:05 UTC Amendment | Peak Bio, Inc. PKBO · Entity 85431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047707 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 F1 · date: On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23. None of those purchases were made. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 16:33 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherWarrant (Right to Purchase) · Derivative | 583,333 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-23-042830 · ownership.xml · derivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,292 Underlying: Common Stock · 583,333 shares Expires 2028-04-28 Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 16:33 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherCommon Stock | 583,333 | $0.60 | $349,999.80 |
DisclosureSEC source: 0000950170-23-042830 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,135,742 Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 16:30 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherWarrant (Right to Purchase) · Derivative | 458,333 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-23-033840 · ownership.xml · derivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 759,625 Underlying: Common Stock · 458,333 shares Expires 2028-04-28 Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 16:30 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherCommon Stock | 458,333 | $0.60 | $274,999.80 |
DisclosureSEC source: 0000950170-23-033840 · ownership.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,552,409 Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:00 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherWarrant (Right to Purchase) · Derivative | 666,667 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000899243-23-016550 · doc4.xml · derivative · entry 3 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,217,958 Underlying: Common Stock · 666,667 shares Expires 2028-04-28 Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:00 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherCommon Stock | 666,667 | $0.60 | $400,000.20 |
DisclosureSEC source: 0000899243-23-016550 · doc4.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,094,076 F1 · balance_after: Due to an administrative error in the Reporting Person's previous Form 4, the number of shares beneficially owned is being corrected in this Form 4 to match the Reporting Person's Schedule 13D filed on March 21, 2023. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 17:16 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $23.09 | $0.00 |
DisclosureSEC source: 0001209191-23-035531 · doc4.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| April 28, 2023 Filed May 2, 2023 16:30 UTC | Peak Bio, Inc. PKBO · Entity 85431 | GrantConvertible Notes · Derivative | Not disclosed | $1,130,775.00 | $1,130,775.00 |
DisclosureSEC source: 0000899243-23-011994 · doc4.xml · derivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-10-28 F2 · derivative.exercise_price: The Convertible Notes accrue interest at 6.0% per annum. At any time prior to maturity, the Reporting Person may convert the unpaid principal amount of the Convertible Notes, together with any accrued but unpaid interest, into shares of the Company's common stock at a price per share equal to $0.60. The Convertible Notes mature on October 28, 2023. F2 · derivative.exercise_date: The Convertible Notes accrue interest at 6.0% per annum. At any time prior to maturity, the Reporting Person may convert the unpaid principal amount of the Convertible Notes, together with any accrued but unpaid interest, into shares of the Company's common stock at a price per share equal to $0.60. The Convertible Notes mature on October 28, 2023. F2 · derivative.underlying_shares: The Convertible Notes accrue interest at 6.0% per annum. At any time prior to maturity, the Reporting Person may convert the unpaid principal amount of the Convertible Notes, together with any accrued but unpaid interest, into shares of the Company's common stock at a price per share equal to $0.60. The Convertible Notes mature on October 28, 2023. Read SEC document |
| April 28, 2023 Filed May 2, 2023 16:30 UTC | Peak Bio, Inc. PKBO · Entity 85431 | GrantWarrant (Right to Purchase) · Derivative | 1,884,625 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0000899243-23-011994 · doc4.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,884,625 Underlying: Common Stock · 1,884,625 shares Expires 2028-04-28 F1 · price: The warrants and convertible promissory notes (the "Convertible Notes") were received in consideration for the conversion of outstanding loans by Dr. Huh to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.